ArticleGastroenterology & hepatology2011
Current concepts in the pathophysiology and management of hepatic encephalopathy.
Article in Gastroenterology & hepatology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Acetyl-L-carnitine for patients with hepatic encephalopathy.The Cochrane database of systematic reviews · 2019Pooled it
- Electroencephalography in hepatic encephalopathy: diagnostic and prognostic applications across the disease spectrum.Annals of gastroenterology · 2026Review
- Retrograde Transcaval Obliteration for Refractory Hepatic Encephalopathy with Multiple Intrahepatic Portosystemic Venous Shunts.Internal medicine (Tokyo, Japan) · 2024Article
- Flapping Tremor: Unraveling Asterixis-A Narrative Review.Medicina (Kaunas, Lithuania) · 2024Review
- Diuretics, SGLT2 inhibitors and falls in older heart failure patients: to prescribe or to deprescribe? A clinical review.European geriatric medicine · 2023Review
- Hyperammonemia in azotemic cats.Journal of feline medicine and surgery · 2021Article
- Identifying areas of improvement in nursing knowledge regarding hepatic encephalopathy management.Journal of community hospital internal medicine perspectives · 2021Article
- Shunt-Induced Hepatic Encephalopathy in TIPS: Current Approaches and Clinical Challenges.Journal of clinical medicine · 2020Review
- Retrograde Transvenous Obliteration (RTO): A New Treatment Option for Hepatic Encephalopathy.Digestive diseases and sciences · 2020Review
- Pancreatic Neuroendocrine Tumor-Induced Hyperammonemic Encephalopathy in the Absence of Hepatic Involvement.ACG case reports journal · 2020Article
- Effects of NHCellular & molecular biology letters · 2016Article
- The expression levels of prolyl oligopeptidase responds not only to neuroinflammation but also to systemic inflammation upon liver failure in rat models and cirrhotic patients.Journal of neuroinflammation · 2015Article
- Article
- Hyponatremia: A Risk Factor for Early Overt Encephalopathy after Transjugular Intrahepatic Portosystemic Shunt Creation.Journal of clinical medicine · 2014Article
- Thioacetamide-induced acute hepatic encephalopathy in rat: behavioral, biochemical and histological changes.Iranian Red Crescent medical journal · 2012Article
- The Current Hepatic Encephalopathy Pipeline.Journal of clinical and experimental hepatologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatic encephalopathy (HE) represents a broad continuum of neuropsychological dysfunction in patients with acute or chronic liver disease and/or portosystemic shunting of blood flow. The pathophysiology of this disease is quite complex, as it involves overproduction and reduced metabolism of various neurotoxins, particularly ammonia. Recent hypotheses implicate low-grade cerebral edema as a final common pathway for the pathophysiology of HE. Management of this condition is multifaceted and requires several steps: elimination of precipitating factors; removal of toxins, both by reducing them at their source and by augmenting scavenging pathways; modulation of resident fecal flora; proper nutritional support; and downregulation of systemic and gut-derived inflammation.
Indexed as
Identifiers
21857820PMC3127024What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.